• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    11/22/22 8:08:06 AM ET
    $AXDX
    $BWAY
    $CYCN
    $GRAY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care
    Get the next $AXDX alert in real time by email

    Gainers

    • OncoSec Medical (NASDAQ:ONCS) shares rose 31.9% to $6.4 during Tuesday's pre-market session. The market value of their outstanding shares is at $11.4 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares rose 20.61% to $0.58. The market value of their outstanding shares is at $7.5 million.
    • BrainsWay (NASDAQ:BWAY) shares moved upwards by 17.8% to $2.25. The company's market cap stands at $37.1 million. As per the news, the Q3 earnings report came out 4 days ago.
    • Cyclerion Therapeutics (NASDAQ:CYCN) shares moved upwards by 16.02% to $0.65. The company's market cap stands at $28.2 million.
    • Accelerate Diagnostics (NASDAQ:AXDX) stock increased by 13.03% to $1.04. The market value of their outstanding shares is at $103.0 million.
    • Marker Therapeutics (NASDAQ:MRKR) stock rose 12.08% to $0.37. The market value of their outstanding shares is at $30.9 million.

    Losers

    • scPharmaceuticals (NASDAQ:SCPH) stock fell 15.1% to $5.17 during Tuesday's pre-market session. The market value of their outstanding shares is at $141.8 million.
    • Hillstream BioPharma (NASDAQ:HILS) stock fell 14.78% to $0.4. The market value of their outstanding shares is at $4.6 million.
    • Graybug Vision (NASDAQ:GRAY) stock fell 14.02% to $0.81. The company's market cap stands at $17.5 million.
    • Tenon Medical (NASDAQ:TNON) shares fell 10.17% to $2.65. The company's market cap stands at $29.7 million.
    • Minerva Surgical (NASDAQ:UTRS) stock decreased by 9.74% to $0.19. The company's market cap stands at $5.5 million.
    • NexImmune (NASDAQ:NEXI) shares decreased by 8.89% to $0.41. The company's market cap stands at $10.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AXDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXDX
    $BWAY
    $CYCN
    $GRAY

    CompanyDatePrice TargetRatingAnalyst
    Marker Therapeutics Inc.
    $MRKR
    3/5/2025$8.00Buy
    Canaccord Genuity
    BrainsWay Ltd.
    $BWAY
    11/16/2023Outperform → Mkt Perform
    Raymond James
    scPharmaceuticals Inc.
    $SCPH
    9/7/2023$20.00Buy
    Craig Hallum
    scPharmaceuticals Inc.
    $SCPH
    12/1/2022$25.00Outperform
    Cowen
    scPharmaceuticals Inc.
    $SCPH
    10/21/2022$14.00Buy
    Jefferies
    scPharmaceuticals Inc.
    $SCPH
    10/11/2022$11.00Mkt Perform → Outperform
    SVB Leerink
    scPharmaceuticals Inc.
    $SCPH
    8/2/2022$10.00Buy
    Maxim Group
    Accelerate Diagnostics Inc.
    $AXDX
    3/9/2022$5.00Buy → Hold
    Craig-Hallum
    More analyst ratings

    $AXDX
    $BWAY
    $CYCN
    $GRAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

    GAD Therapies Market Set to Explode to $4.26B by 2033 as Demand Rockets for Innovative Anxiety Solutions NEW YORK, March 5, 2026 /CNW/ -- Market News Updates News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news for millions of people dealing with constant worry and stress. Traditional medications like anti-anxiety drugs and antidepressants still play a big role, but therapy options such as cognitive-behavioral therapy and mindfulness techniques are also helping people manage symptoms without relying only on medication. Digital mental health tools and telehealth visits are making treatment easier to access, especially f

    3/5/26 9:30:00 AM ET
    $ACHC
    $AIFF
    $BWAY
    Medical Specialities
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Landmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

    BURLINGTON, Mass. and JERUSALEM, March 04, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) unveiled new clinical data showing a significantly faster, noninvasive way to treat depression without compromising the efficacy of one of psychiatry's most impactful treatments. The milestone advances BrainsWay's brain health vision and sets the stage for a neuromodulation platform that transforms lives. Two new peer-reviewed manuscripts in Brain Stimulation found that BrainsWay's exclusive FDA-cleared SWIFT™ accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) protocol for the treatment of Major Depressive Disorder (MDD) achieved comparable remission and response rates when

    3/4/26 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

    TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash"). TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by

    3/3/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $BWAY
    $CYCN
    $GRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Williamson Kevin converted options into 1,041 shares, increasing direct ownership by 2% to 43,593 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    3/5/26 4:37:46 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    CEO and President Foster Steven M converted options into 140,936 shares, increasing direct ownership by 616% to 163,814 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    1/5/26 8:52:17 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Director Hochschuler Stephen converted options into 10,732 shares and covered exercise/tax liability with 3,327 shares, increasing direct ownership by 1,389% to 7,938 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    1/5/26 8:52:01 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    $AXDX
    $BWAY
    $CYCN
    $GRAY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FUROSCIX issued to SCPHARMACEUTICALS INC

    Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form

    10/11/22 1:54:57 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $BWAY
    $CYCN
    $GRAY
    SEC Filings

    View All

    SEC Form PRE 14A filed by Marker Therapeutics Inc.

    PRE 14A - Marker Therapeutics, Inc. (0001094038) (Filer)

    3/10/26 4:59:15 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by BrainsWay Ltd.

    6-K - Brainsway Ltd. (0001505065) (Filer)

    3/5/26 6:00:11 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by TransCode Therapeutics Inc.

    DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:06:34 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $BWAY
    $CYCN
    $GRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Foster Steven M bought 19,455 shares, increasing direct ownership by 568% to 22,878 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    11/18/25 8:42:50 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Chief Innovation Officer Geist Wyatt D. bought 19,455 shares, increasing direct ownership by 14% to 157,569 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    11/18/25 8:01:43 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Grawey Nathaniel A. bought 101,167 shares, increasing direct ownership by 73% to 239,281 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    11/18/25 8:01:06 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    $AXDX
    $BWAY
    $CYCN
    $GRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Marker International with a new price target

    Canaccord Genuity initiated coverage of Marker International with a rating of Buy and set a new price target of $8.00

    3/5/25 7:37:58 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brainsway downgraded by Raymond James

    Raymond James downgraded Brainsway from Outperform to Mkt Perform

    11/16/23 7:31:55 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Craig Hallum initiated coverage on scPharmaceuticals with a new price target

    Craig Hallum initiated coverage of scPharmaceuticals with a rating of Buy and set a new price target of $20.00

    9/7/23 9:06:27 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $BWAY
    $CYCN
    $GRAY
    Leadership Updates

    Live Leadership Updates

    View All

    Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

    –Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC") Study in Treatment Resistant Depression ("TRD") in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) ("Cyclerion" or "Company"), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory feedback and responses from the FDA on CYC-126

    2/17/26 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $BWAY
    $CYCN
    $GRAY
    Financials

    Live finance-specific insights

    View All

    BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026

    BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, March 11, 2026Time:8:30 AM Eastern TimeUnited States:1-877-300-8521Internationa

    2/25/26 8:00:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

    Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024 Operating income totaled $1.3 million and Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025, as compared with Q3 2024 Remaining performance obligations increased to $65 million FDA cleared an accelerated protocol for Deep TMS treatment of patients with major depressive disorder (MDD) Raised midpoint of full-year 2025 Revenue and EBITDA guidance Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatm

    11/11/25 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025

    BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, November 11, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the financial results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, November 11, 2025Time:8:30 AM Eastern TimeUnited States:1-8

    10/28/25 8:00:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $AXDX
    $BWAY
    $CYCN
    $GRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

    SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

    11/15/24 4:06:50 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

    SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

    11/14/24 5:48:35 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care